Company / Capital Expenditures
Inhibrx Biosciences, Inc. Capital Expenditures History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$31.0K
FY2025
5-year range
$31.0K / $4.6M
FY2023-FY2025
Trend
-99.3%
vs FY2024
Sector context
#184 of 194
Health Care
What the data says
Among 194 Health Care companies, Inhibrx Biosciences, Inc. is in the bottom 5% for capital expenditures. Declined from $5M to $31,000 over the past 2 years.
Based on SEC 10-K filings.
$31,000 in FY2025.
Declined from $5M to $31,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 194This company $31.0K Sector average $117.5M
▼
-100.0% below sector average
Key checks
Key Insights
- In FY2025, capital expenditures decreased 99.3% year-over-year.
- Ranks #184 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -3.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $31.0K | -99.3% |
| FY2024 | $4.6M | +0.0% |
| FY2023 | $4.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026